Klinik für Urologie und Kinderurologie

Studien zur überaktiven Blase und Harnblasenkarzinom

Dysport
A phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of Dysport® for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. 
THE LEADERSHIP 301 TRIAL
Studie in VorbereitungThe LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods
 
 
 
 

Anmeldung und Information

Montag bis Freitag: 8 - 16 Uhr
T +49 (0)251- 83 49 94 9
T +49 (0)251- 83 47 44 6
F +49 (0)251 - 83 57 29 6